Opinion|Videos|January 31, 2025
Switching Between BTK Inhibitors in CLL
Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease progression, drug interactions, and patient preferences, with pirtobrutinib emerging as a particularly valuable option for patients with BTK C481 mutations or those who have exhausted other BTK inhibitor (BTKi) options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors typically drive decisions to switch between BTK inhibitors: managing toxicity, addressing disease progression, or other considerations?
- How do these factors influence your decision on which therapy to switch to, either within the BTKi class or outside of it? Where does pirtobrutinib fit into this decision?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5